Takeda

News

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

News

MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.

News

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

News

The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

Sales & Marketing

Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?